UHS Beats Q2 Estimates but Trims EPS Outlook as Costs Rise
UHS is trading near its 52-week low of $140.08 (9.2% above the low).
Summary
UHS posted Q2 revenue of $4.64B and EPS of $5.98, beating estimates, but lowered its full-year Adjusted EPS guidance midpoint by 2.6% due to cost pressures and the non-recurrence of certain Medicaid benefits. The company also repurchased $320M in shares during the quarter.
Key Events · Earnings and Guidance · UHS
-
Q2 Revenue and EPS Beat
Net revenues of $4.638B (+8.3% YoY) exceeded the $4.58B consensus; diluted EPS of $5.98 compared to $5.43 in Q2 2025.
-
Full-Year EPS Guidance Lowered
Revised 2026 Adjusted EPS-diluted guidance range of $22.28–$23.65, with the midpoint down 2.6% from the original forecast, driven by cost pressures and the non-recurrence of certain Florida Medicaid benefits.
-
Significant Share Repurchases
Repurchased 1.89M shares for $320.3M in Q2 2026 (avg. $169/share); YTD repurchases total 2.565M shares for $447.5M, with $977.6M remaining under authorization.
-
Self-Insured Liability Reserve Increase
Recorded an unfavorable $28M pre-tax charge to increase reserves for self-insured professional and general liability claims, highlighting ongoing litigation exposure.
Analysis · UHS · Industrial Applications And Services
Universal Health Services turned in a solid second quarter, with revenue of $4.64B surpassing consensus and EPS reaching $5.98, yet the revised full-year guidance paints a more nuanced picture. While the revenue midpoint edged higher, the Adjusted EPS midpoint fell 2.6% to $22.97, reflecting mounting cost pressures and the absence of expected Florida Medicaid benefits beyond Q2. A $28M increase in self-insured liability reserves also surfaced, underscoring persistent legal risks. On the capital allocation front, aggressive buybacks continued—$320M in Q2 alone—which bolsters EPS but constrains cash for other purposes. For investors, the earnings call and updated forecast offer critical data points to weigh strong operational performance against margin headwinds and litigation overhang.
At the time of this filing, UHS was trading at $152.96 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9.6B. The 52-week trading range was $140.08 to $246.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.